Alaunos Therapeutics (TCRT) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Alaunos Therapeutics
Is Alaunos Therapeutics a buy right now? The alternative data says hold. This TCRT stock analysis is built on the 25+ alternative data signals AltIndex tracks on Alaunos Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 48/100: a Hold. The stock trades at $0.78 with a $2M market cap.
The soft spots over the past 90 days: headcount (according to LinkedIn) down 11.1% to 8 employees, and web traffic down 5.0% to 2K monthly visits. The rest of the signal set is holding steady, which keeps TCRT at a hold rather than a sell.
TCRT’s broader alt-data profile also covers sentiment (100/100). Every signal links to its own page with full history, the TCRT technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on TCRT is just below.
Alaunos Therapeutics AI Stock Analysis
Alaunos Therapeutics is a biopharmaceutical company focused on innovating and delivering therapies in the field of oncology. The company's research and development efforts are centered around cutting-edge treatments to target difficult-to-treat cancers.
Analysis generated October 1, 2026.
Recent Alaunos Therapeutics Stock Alerts
|
Alaunos Therapeutics | October 8 Price is down by -6.3% in the last 24h. |
|
Alaunos Therapeutics | October 7 Price is up by 7.8% in the last 24h. |
|
Alaunos Therapeutics | October 6 Price is down by -9.6% in the last 24h. |
|
Alaunos Therapeutics | October 2 Price is down by -6.5% in the last 24h. |
Alaunos Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 2K | 5.0% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 8 | 11.1% | |
| Employee Recommend | 35 | 0% | |
| Business Outlook | 0 | N/A | |
| Sentiment | 100 | N/A | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 20 | 233.3% | |
| Stocktwits Mentions | 4 | N/A | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 9K | 0% |
About Alaunos Therapeutics (TCRT)
Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.
| Price | $0.78 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $2M |
| Year Range | $1 – $4 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Alaunos Therapeutics News
View more →
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse StudyJune 29 - GlobeNewswire |
|
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesMay 26 - GlobeNewswire |
See Alaunos Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for TCRT, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEAlaunos Therapeutics Earnings & Financial Performance
View all earnings →Alaunos Therapeutics Insider Trading Activity
View all →| Postma Robert W filed to sell 600 shares at $0.0. Jun 24 '25 |
| Vieser Jaime filed to sell 250 shares at $0.0. Jun 24 '25 |
| Postma Robert W filed to sell 500 shares at $0.0. Apr 11 '25 |
| Postma Robert W filed to sell 500 shares at $0.0. Apr 11 '25 |
| Vieser Jaime filed to sell 25,894 shares at $0.0. Dec 31 '24 |
Alaunos Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Alaunos Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
GenprexGNPX |
$2.75 5.0% | $2M | 46 |
 |
Clearside BiomedicalCLSD |
$0.41 27.0% | $2M | 45 |
 |
OragenicsOGEN |
$0.46 7.4% | $2M | 53 |
 |
Hepion PharmaceuticalsHEPA |
$0.13 4.2% | $2M | 57 |
 |
BioXcel TherapeuticsBTAI |
$0.07 37.1% | $2M | 45 |
Explore Alaunos Therapeutics Data
Frequently Asked Questions: Alaunos Therapeutics (TCRT)
Alaunos Therapeutics has an AltIndex AI Score of 48/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
48/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Alaunos Therapeutics (TCRT) stock is $0.78 with a market cap of $2M.
As of today, Alaunos Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Alaunos Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Alaunos Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The TCRT stock price chart above shows Alaunos Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Alaunos Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Alaunos Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
